Followers | 88 |
Posts | 8196 |
Boards Moderated | 0 |
Alias Born | 06/17/2013 |
Monday, May 20, 2019 9:43:51 PM
https://biomedix.com/products/padnet/padnet-faq/
It isn't just about the merger w/ Diabetes Relief , it's also about AngioSoma using PADnet devices in their Phase 3 clinical trial for diagnostics on the fly . IMO
AngioSoma Creates New Partnership Opportunity
Peripheral Artery Disease Device Manufacturer Targeted for Joint Venture
https://globenewswire.com/news-release/2018/11/13/1650297/0/en/AngioSoma-Creates-New-Partnership-Opportunity.html
HOUSTON, Nov. 13, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma (OTC: SOAN), a leading biotechnology research and development company, announces today the execution of a letter of intent to pursue a relationship with Biomedix®.
Biomedix® manufactures a noninvasive device, PADnet, that diagnoses Peripheral Artery Disease (PAD) in patients. Biomedix has over 1,000 PADnet devices under service throughout the United States and can potentially assist in our clinical trials and research, once we determine the scope and breadth of the services needed. We could potentially engage with Biomedix to:
1. Leverage PADnet technology, but using doctors and patients managed by another clinical research partner
2. Leverage PADnet technology through doctors willing to participate, that meets our specifications, such as geography and medical specialty, to assist in the trials.
3. Leverage PADnet technology through identified patients willing to participate, that meets our specifications, such as disease severity and associated risk factors, to assist with the trials
AngioSoma intends to use the PADnet device to select patients for clinical trials and determine the presence and severity of PAD in patients before and after using Liprostin™, its flagship patented pharmaceutical intervention for PAD. Liprostin™ is currently in the approval process of the FDA for marketing. Combining these tightly aligned products will assist doctors in providing the best care possible and give patients peace of mind that interventions are working.
“It’s a natural fit for us,” said Alex Blankenship, President of AngioSoma. “The ability to verify the effectiveness of treatment by testing before and after interventions will enhance our efficacy data, leading to greater visibility for our products going forward.”
Recent GSTC News
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 07:23:46 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/17/2024 08:05:07 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 02/15/2024 04:33:13 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 01/19/2024 10:13:47 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 01/02/2024 09:21:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 05:32:02 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM